Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.

Publication ,  Journal Article
Yang, CS; Khawly, JA; Hainsworth, DP; Chen, SN; Ashton, P; Guo, H; Jaffe, GJ
Published in: Arch Ophthalmol
January 1998

OBJECTIVE: To determine the efficacy and pharmacokinetics of an intravitreal sustained-release triamcinolone acetonide and 5-fluorouracil (TA/5-FU) codrug in the treatment of experimental proliferative vitreoretinopathy (PVR). METHODS: The therapeutic efficacy of the TA/5-FU codrug was determined in a rabbit model that simulates human PVR. Intravitreal levels of triamcinolone and 5-fluorouracil were measured at different time points and drug release in vitro was tested. Toxic effects were evaluatedby electroretinograpy, clinical examination, and light microscopy. RESULTS: Both the severity of PVR grade and the percentage of eyes with moderate or worse tractional detachment were significantly less in eyes treated with the codrug. The therapeutic effect of the intravitreal codrug was paralleled by sustained intravitreal levels of triamcinolone and 5-fluorouracil. There were no drug-related toxic effects evident on clinical or histopathologic examination of eyes containing the TA/5-FU codrug. CONCLUSIONS: The intravitreal sustained-release TA/5-FU codrug effectively inhibits the progression of PVR in a rabbit model that closely resembles PVR in humans. The TA/5-FU codrug may simultaneously target different components of the wound-healing response.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Arch Ophthalmol

DOI

ISSN

0003-9950

Publication Date

January 1998

Volume

116

Issue

1

Start / End Page

69 / 77

Location

United States

Related Subject Headings

  • Vitreous Body
  • Vitreoretinopathy, Proliferative
  • Triamcinolone
  • Treatment Outcome
  • Rabbits
  • Ophthalmology & Optometry
  • Injections
  • Immunosuppressive Agents
  • Glucocorticoids
  • Fluorouracil
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Yang, C. S., Khawly, J. A., Hainsworth, D. P., Chen, S. N., Ashton, P., Guo, H., & Jaffe, G. J. (1998). An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol, 116(1), 69–77. https://doi.org/10.1001/archopht.116.1.69
Yang, C. S., J. A. Khawly, D. P. Hainsworth, S. N. Chen, P. Ashton, H. Guo, and G. J. Jaffe. “An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.Arch Ophthalmol 116, no. 1 (January 1998): 69–77. https://doi.org/10.1001/archopht.116.1.69.
Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, et al. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998 Jan;116(1):69–77.
Yang, C. S., et al. “An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy.Arch Ophthalmol, vol. 116, no. 1, Jan. 1998, pp. 69–77. Pubmed, doi:10.1001/archopht.116.1.69.
Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jaffe GJ. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998 Jan;116(1):69–77.

Published In

Arch Ophthalmol

DOI

ISSN

0003-9950

Publication Date

January 1998

Volume

116

Issue

1

Start / End Page

69 / 77

Location

United States

Related Subject Headings

  • Vitreous Body
  • Vitreoretinopathy, Proliferative
  • Triamcinolone
  • Treatment Outcome
  • Rabbits
  • Ophthalmology & Optometry
  • Injections
  • Immunosuppressive Agents
  • Glucocorticoids
  • Fluorouracil